BridgeBio Pharma Inc.
BridgeBio Pharma Enters New Equity Distribution Agreement
Summary
On May 7, 2026, BridgeBio Pharma, Inc. entered into a new Equity Distribution Agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC, allowing the company to issue and sell up to $500,000,000 of its common stock through the Sales Agents. This new agreement replaces the prior Equity Distribution Agreement, dated May 4, 2023, which was terminated on the same day. The Company is not obligated to make any sales of Common Stock, and the Sales Agents are not required to sell any specific number or dollar amount of shares of the Common Stock under the new Agreement.
Profitelligence Alerts
Get alerts for BBIO
Be first to know when BridgeBio Pharma Inc. files with the SEC.
Filing Categories
Advertisement
About BridgeBio Pharma Inc.
BridgeBio Pharma Inc. is a cutting-edge biotechnology company focused on discovering, developing, and delivering transformative medicines for patients with genetic diseases. The company's primary purpose is to bridge the gap in medical research and bring breakthrough therapies to those with rare and often overlooked genetic disorders. By utilizing a targeted approach, BridgeBio Pharma Inc. works across multiple sectors including dermatology, oncology, cardiology, neurology, and endocrinology. The company partners with academic institutions, research organizations, and industry leaders to harness the latest scientific advancements in genomics and biotechnology. Established with a mission to translate genetic research into real-world medical solutions, BridgeBio Pharma Inc. plays a significant role in the biopharmaceutical market. It is heavily involved in the early and late stages of drug development, positioning itself as a key player in the quest to address unmet medical needs. This focus on genetic-centric therapies underlines its importance in the rapidly evolving landscape of biotechnology and personalized medicine.
Official SEC Documents
Advertisement